Michael Charles Heinrich

List of Publications by Year in Descending Order

241 papers	36,386 citations	85 h-index	190 g-index
255 ext. papers	40,090 ext. citations	7.7 avg, IF	6.62 L-index

#	Paper	IF	Citations
241	PHASE 2 STUDY OF PONATINIB IN ADVANCED GASTROINTESTINAL STROMAL TUMORS: EFFICACY, SAFETY, AND IMPACT OF LIQUID BIOPSY AND OTHER BIOMARKERS.. *Clinical Cancer Research*, **2022** ,	12.9	4
240	New treatment strategies for advanced-stage gastrointestinal stromal tumours.. *Nature Reviews Clinical Oncology*, **2022**,	19.4	6
239	A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor.. *BMC Cancer*, **2022**, 22, 511	4.8	1
238	Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data. *BMC Cancer*, **2021**, 21, 291	4.8	5
237	Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. *European Journal of Cancer*, **2021**, 145, 132-142	7.5	24
236	Disease-free Interval Is Associated with Oncologic Outcomes in Patients with Recurrent Gastrointestinal Stromal Tumor. *Annals of Surgical Oncology*, **2021**, 28, 7912-7920	3.1	1
235	Inhibition of KIT Tyrosine Kinase Activity: Two Decades After the First Approval. *Journal of Clinical Oncology*, **2021**, 39, 1674-1686	2.2	2
234	Imatinib-resistant gastrointestinal stromal tumors in the era of second- and third-line tyrosine kinase inhibitors: Does surgical resection have a role?. *Surgery*, **2021**, 170, 1481-1486	3.6	
233	Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity. *Clinical Cancer Research*, **2021**,	12.9	2
232	Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain. *Cancer Discovery*, **2021**, 11, 108-125	24.4	23
231	Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis. *Oncogene*, **2021**, 40, 1957-1973	9.2	8
230	Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor. *Frontiers in Oncology*, **2021**, 11, 672500	5.3	6
229	Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. *Oncologist*, **2021**, 26, e2053-e2060	5.7	3
228	Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. *European Journal of Cancer*, **2021**, 155, 236-244	7.5	2
227	Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous Mutations in the Phase III INVICTUS Study. *Clinical Cancer Research*, **2021**, 27, 6333-6342	12.9	4
226	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. *Journal of Clinical Oncology*, **2021**, 39, 3128-3139	2.2	12
225	Identification of Wee1 as a target in combination with avapritinib for gastrointestinal stromal tumor treatment. *JCI Insight*, **2021**, 6,	9.9	4

224	Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes. *Leukemia and Lymphoma*, **2020**, 61, 2511-2514	1.9	1
223	Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncology, The*, **2020**, 21, 923-934	21.7	102
222	Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. *Lancet Oncology, The*, **2020**, 21, 935-946	21.7	101
221	Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. *Future Oncology*, **2020**, 16, 4251-4264	3.6	28
220	Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study. *Clinical Cancer Research*, **2020**, 26, 1837-1845	12.9	19
219	A smooth muscle-derived, Braf-driven mouse model of gastrointestinal stromal tumor (GIST): evidence for an alternative GIST cell-of-origin. *Journal of Pathology*, **2020**, 252, 441-450	9.4	7
218	Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. *Journal of Clinical Oncology*, **2020**, 38, 3294-3303	2.2	31
217	Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. *Cancer Cell*, **2019**, 36, 431-443.e5	24.3	63
216	Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced - or -mutated melanoma. *Oncotarget*, **2019**, 10, 1850-1859	3.3	12
215	Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. *Cancer Cell*, **2019**, 35, 738-751.e9	24.3	93
214	Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry. *Clinical Sarcoma Research*, **2019**, 9, 4	2.5	11
213	Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis. *Leukemia and Lymphoma*, **2019**, 60, 2384-2393	1.9	4
212	Genomic aberrations in cell cycle genes predict progression of -mutant gastrointestinal stromal tumors (GISTs). *Clinical Sarcoma Research*, **2019**, 9, 3	2.5	11
211	KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy. *Molecular Cancer Therapeutics*, **2019**, 18, 1985-1996	6.1	15
210	Clinical activity of avapritinib in fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).. *Journal of Clinical Oncology*, **2019**, 37, 11022-11022	2.2	13
209	Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. *British Journal of Cancer*, **2019**, 120, 612-620	8.7	62
208	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. *New England Journal of Medicine*, **2019**, 381, 2315-2326	59.2	114
207	LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma. *Oncogene*, **2019** , 38, 1200-1210	9.2	12

206	Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	19
205	Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618.. *Journal of Clinical Oncology*, **2018**, 36, 11511-11511	2.2	3
204	Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases. *Pharmacology & Therapeutics*, **2018**, 191, 123-134	13.9	21
203	MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. *Nature Communications*, **2017**, 8, 14674	17.4	38
202	PDGFRA Antibody for Soft Tissue Sarcoma. *Cell*, **2017**, 168, 555	56.2	6
201	Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. *JAMA Oncology*, **2017**, 3, 944-952	13.4	49
200	CKIT **2017**, 683-692		
199	Defining the Impact of Adjuvant Therapy in Molecularly Defined Subsets of Gastrointestinal Stromal Tumor : From Lumping to Splitting. *JAMA Oncology*, **2017**, 3, 597-599	13.4	3
198	Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors. *Expert Review of Molecular Diagnostics*, **2017**, 17, 445-457	3.8	17
197	A precision therapy against cancers driven by mutations. *Science Translational Medicine*, **2017**, 9,	17.5	91
196	Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown Significance. *Clinical Cancer Research*, **2017**, 23, 6733-6743	12.9	8
195	Gastrointestinal stromal tumours of the oesophagus: a clinicopathological and molecular analysis of 27 cases. *Histopathology*, **2017**, 71, 805-812	7.3	7
194	Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST).. *Journal of Clinical Oncology*, **2017**, 35, 11011-11011	2.2	15
193	A randomized, double-blind, placebo-controlled, phase III study of crenolanib in advanced or metastatic GIST patients bearing a D842V mutation in PDGFRA: The CrenoGIST study.. *Journal of Clinical Oncology*, **2017**, 35, TPS11080-TPS11080	2.2	9
192	FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. *Journal of Translational Medicine*, **2016**, 14, 339	8.5	113
191	Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. *BMC Cancer*, **2016**, 16, 22	4.8	43
190	Combining the Allosteric ABL1 Tyrosine Kinase Inhibitor ABL001 with ATP-Competitive Inhibitors to Suppress Resistance in Chronic Myeloid Leukemia. *Blood*, **2016**, 128, 2747-2747	2.2	2
189	Conjoined hyperactivation of the RAS and PI3K pathways in advanced GIST.. *Journal of Clinical Oncology*, **2016**, 34, e22520-e22520	2.2	4

188	Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. *Annals of Oncology*, **2016**, 27, 1794-9	10.3	63
187	Regorafenib for treatment of imatinib- and sunitinib-resistant metastatic gastrointestinal stromal tumors. *Expert Opinion on Orphan Drugs*, **2016**, 4, 659-670	1.1	
186	Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. *European Journal of Cancer*, **2016**, 61, 94-101	7.5	19
185	Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib. *Oncotarget*, **2016**, 7, 41390-41403	3.3	39
184	Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. *Clinical Cancer Research*, **2015**, 21, 2289-96	12.9	90
183	Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance. *Cancer Research*, **2015**, 75, 880-91	10.1	64
182	SDHC methylation in gastrointestinal stromal tumors (GIST): a case report. *BMC Medical Genetics*, **2015**, 16, 87	2.1	16
181	S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors. *Oncologist*, **2015**, 20, 1353-4	5.7	9
180	Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways. *Cancer Medicine*, **2015**, 4, 101-3	4.8	61
179	KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation. *Journal of Clinical Oncology*, **2015**, 33, e93-6	2.2	39
178	Genotyping and immunohistochemistry of gastrointestinal stromal tumors: An update. *Seminars in Diagnostic Pathology*, **2015**, 32, 392-9	4.3	27
177	CKIT **2015**, 1-9		
176	Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. *Journal of Clinical Oncology*, **2014**, 32, 1563-70	2.2	192
175	Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract. *Journal of the American Academy of Dermatology*, **2014**, 71, 229-36	4.5	32
174	Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST). *BMC Cancer*, **2014**, 14, 685	4.8	61
173	Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. *Clinical Cancer Research*, **2014**, 20, 5745-5755	12.9	113
172	Regorafenib for treatment of advanced gastrointestinal stromal tumors. *Expert Opinion on Pharmacotherapy*, **2014**, 15, 549-58	4	13
171	Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer. *Clinical Cancer Research*, **2014**, 20, 1306-12	12.9	16

170	Combination therapy for KIT-mutant mast cells: targeting constitutive NFAT and KIT activity. *Molecular Cancer Therapeutics*, **2014**, 13, 2840-51	6.1	6
169	A phase 2 study of ponatinib in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after failure of tyrosine kinase inhibitor (TKI) therapy: Initial report.. *Journal of Clinical Oncology*, **2014**, 32, 10506-10506	2.2	16
168	Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. *Molecular Cancer*, **2013**, 12, 46	42.1	46
167	Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. *Molecular Cancer*, **2013**, 12, 19	42.1	80
166	Gastrointestinal stromal tumors: molecular markers and genetic subtypes. *Hematology/Oncology Clinics of North America*, **2013**, 27, 871-88	3.1	42
165	Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. *Nature Genetics*, **2013**, 45, 131-2	36.3	386
164	Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. *Journal of Molecular Diagnostics*, **2013**, 15, 171-6	5.1	107
163	Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. *Journal of Clinical Oncology*, **2013**, 31, 3182-90	2.2	409
162	Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA. *Cancer Medicine*, **2013**, 2, 21-31	4.8	25
161	Combination Therapy In Mast Cell Neoplasms: Co-Targeting KIT and NFAT Signaling Pathways. *Blood*, **2013**, 122, 4105-4105	2.2	
160	Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study. *Histopathology*, **2012**, 61, 801-9	7.3	74
159	Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. *Annals of Surgical Oncology*, **2012**, 19, 1074-80	3.1	138
158	Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia. *Leukemia*, **2012**, 26, 2144-6	10.7	50
157	Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. *Journal of Clinical Oncology* , **2012**, 30, 2401-7	2.2	192
156	Multiplex high-throughput gene mutation analysis in acute myeloid leukemia. *Human Pathology*, **2012**, 43, 2167-76	3.7	16
155	Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. *Medical Oncology*, **2012**, 29, 1765-72	3.7	72
154	Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. *Molecular Cancer Therapeutics*, **2012**, 11, 1770-80	6.1	55
153	Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. *Clinical Cancer Research*, **2012**, 18, 4375-84	12.9	164

152	Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1. *American Journal of Hypertension*, **2012**, 25, 1118-23	2.3	35
151	Management of tyrosine kinase inhibitor-resistant gastrointestinal stromal tumors. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2012**, 663-8	7.1	2
150	Survey of activated FLT3 signaling in leukemia. *PLoS ONE*, **2011**, 6, e19169	3.7	46
149	"Pediatric-type" gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior. *American Journal of Surgical Pathology*, **2011**, 35, 495-504	6.7	85
148	Immunohistochemical and molecular markers in breast phyllodes tumors. *Applied Immunohistochemistry and Molecular Morphology*, **2011**, 19, 119-25	1.9	35
147	Differential expression of neural markers in KIT and PDGFRA wild-type gastrointestinal stromal tumours. *Histopathology*, **2011**, 59, 1071-80	7.3	21
146	Gastrointestinal stromal tumours: origin and molecular oncology. *Nature Reviews Cancer*, **2011**, 11, 865-78	31.3	565
145	SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing. *Journal of the National Cancer Institute*, **2011**, 103, 983-7	9.7	125
144	Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. *Journal of Molecular Diagnostics*, **2011**, 13, 504-13	5.1	68
143	The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3□dependent pathway. *Molecular Cancer Therapeutics*, **2011**, 10, 949-59	6.1	18
142	A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. *Laboratory Investigation*, **2010**, 90, 1285-94	5.9	71
141	A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells. *Leukemia*, **2010**, 24, 44-50	10.7	58
140	MET receptor sequence variants R970C and T992I lack transforming capacity. *Cancer Research*, **2010**, 70, 6233-7	10.1	63
139	A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331). *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2010**, 33, 495-9	2.7	72
138	High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast. *Modern Pathology*, **2010**, 23, 27-37	9.8	90
137	Imatinib treatment of metastatic GIST: don□t stop (believing). *Lancet Oncology, The*, **2010**, 11, 910-1	21.7	12
136	Primary extragastrointestinal stromal tumor of the pleura: report of a unique case with genetic confirmation. *American Journal of Surgical Pathology*, **2010**, 34, 907-12	6.7	46
135	Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. *Blood*, **2010**, 115, 2372-9	2.2	135

134	Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas. *Endocrine Pathology*, **2010**, 21, 73-9	4.2	28
133	Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. *Breast Cancer Research and Treatment*, **2010**, 120, 409-18	4.4	97
132	RNAi screen for rapid therapeutic target identification in leukemia patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 8695-700	11.5	88
131	Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors. *Clinical Cancer Research*, **2009**, 15, 7510-7518	12.9	165
130	The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. *Cell Cycle*, **2009**, 8, 2621-30	4.7	26
129	Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. *Clinical Cancer Research*, **2009**, 15, 5902-9	12.9	114
128	Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor. *Molecular Cancer Therapeutics*, **2009**, 8, 2172-82	6.1	45
127	Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. *Molecular Cancer Therapeutics*, **2009**, 8, 481-9	6.1	17
126	Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. *International Journal of Cancer*, **2009**, 125, 2991-4	7.5	66
125	Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. *Journal of Surgical Oncology*, **2009**, 99, 42-7	2.8	296
124	Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. *Pediatric Blood and Cancer*, **2009**, 52, 767-71	3	124
123	Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. *Leukemia Research*, **2009**, 33, 735-41	2.7	62
122	Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia. *Haematologica*, **2009**, 94, 46-53	6.6	13
121	High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. *Blood*, **2009**, 113, 1749-55	2.2	97
120	FLT3 and KIT Isoforms Activate PI3K/AKT Signaling Which Is Potently Blocked by the Novel Dual PI3K/Mtor Inhibitors NVP-BEZ235 and NVP-BGT226.. *Blood*, **2009**, 114, 1740-1740	2.2	1
119	An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia. *Leukemia*, **2008**, 22, 2269-72	10.7	28
118	Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. *Modern Pathology*, **2008**, 21, 476-84	9.8	148
117	MicroRNA expression signature of human sarcomas. *Oncogene*, **2008**, 27, 2015-26	9.2	199

116	Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. *Journal of Clinical Oncology*, **2008**, 26, 620-5	2.2	781
115	Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. *Journal of Clinical Oncology*, **2008**, 26, 5352-9	2.2	583
114	Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. *Journal of Clinical Oncology*, **2008**, 26, 5360-7	2.2	480
113	Major response to imatinib mesylate in KIT-mutated melanoma. *Journal of Clinical Oncology*, **2008**, 26, 2046-51	2.2	373
112	KIT gene mutations and copy number in melanoma subtypes. *Clinical Cancer Research*, **2008**, 14, 6821-8	12.9	532
111	Imatinib targeting of KIT-mutant oncoprotein in melanoma. *Clinical Cancer Research*, **2008**, 14, 7726-32	12.9	116
110	Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. *Journal of Clinical Oncology*, **2008**, 26, 4659-65	2.2	163
109	Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. *Journal of Clinical Oncology*, **2008**, 26, 626-32	2.2	801
108	Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. *Clinical Cancer Research*, **2008**, 14, 2717-25	12.9	154
107	Molecular pathobiology of gastrointestinal stromal sarcomas. *Annual Review of Pathology: Mechanisms of Disease*, **2008**, 3, 557-86	34	239
106	RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. *Blood*, **2008**, 111, 2238-45	2.2	62
105	High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. *Blood*, **2008**, 111, 4788-96	2.2	77
104	A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. *American Journal of Surgical Pathology*, **2008**, 32, 210-8	6.7	350
103	Epithelioid gastric stromal tumours of the antrum in young females with the Carney triad: A report of three new cases with mutational analysis and comparative genomic hybridization. *Oncology Reports*, **2007**,	3.5	3
102	Primary adenoid cystic carcinoma of the lung: absence of KIT mutations. *Cancer*, **2007**, 110, 2507-10	6.4	40
101	Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. *Leukemia*, **2007**, 21, 489-93	10.7	69
100	Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. *Cancer Cell*, **2007**, 12, 501-13	24.3	154
99	Mitotic recombination as evidence of alternative pathogenesis of gastrointestinal stromal tumours in neurofibromatosis type 1. *Journal of Medical Genetics*, **2007**, 44, e61	5.8	48

98	Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. *Clinical Cancer Research*, **2007**, 13, 5398-405	12.9	100
97	Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. *Cancer Research*, **2007**, 67, 9084-8	10.1	136
96	A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. *Blood*, **2007**, 110, 323-33	2.2	38
95	BRAF in papillary thyroid carcinoma of ovary (struma ovarii). *American Journal of Surgical Pathology*, **2007**, 31, 1337-43	6.7	75
94	Gastrointestinal stromal tumour. *Lancet, The*, **2007**, 369, 1731-41	40	466
93	MEHrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach. *Journal of Clinical Investigation*, **2007**, 117, 70-80	15.9	86
92	Epithelioid gastric stromal tumours of the antrum in young females with the Carney triad: a report of three new cases with mutational analysis and comparative genomic hybridization. *Oncology Reports*, **2007**, 18, 9-15	3.5	28
91	Activating alleles of JAK3 in acute megakaryoblastic leukemia. *Cancer Cell*, **2006**, 10, 65-75	24.3	265
90	Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. *Cancer Research*, **2006**, 66, 473-81	10.1	398
89	Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). *Journal of Clinical Oncology*, **2006**, 24, 1195-203	2.2	248
88	Does tumor mutational status correlate with clinical response to imatinib?. *Nature Clinical Practice Oncology*, **2006**, 3, 600-1		3
87	Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. *Journal of Clinical Oncology*, **2006**, 24, 4764-74	2.2	652
86	Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. *Lancet, The*, **2006**, 368, 1329-38	40	2004
85	Molecular basis for treatment of gastrointestinal stromal tumours. *European Journal of Cancer, Supplement*, **2006**, 4, 10-18	1.6	8
84	Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. *Journal of Molecular Diagnostics*, **2006**, 8, 604-12	5.1	29
83	Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma. *Journal of Urology*, **2006**, 175, 53-6	2.5	17
82	Ectodermally derived steel/stem cell factor functions non-cell autonomously during primitive erythropoiesis in Xenopus. *Blood*, **2006**, 107, 3114-21	2.2	8
81	Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. *Blood*, **2006**, 108, 3674-81	2.2	224

80	Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall. *International Journal of Gynecological Pathology*, **2006**, 25, 288-92	3.2	64
79	Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2006**, 29, 12-3	2.7	85
78	Dermatofibrosarcoma protuberans: a partial response to imatinib therapy. *Dermatologic Surgery*, **2006**, 32, 456-9	1.7	25
77	FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). *Leukemia*, **2006**, 20, 2008-14	10.7	36
76	Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. *Leukemia Research*, **2006**, 30, 1097-104	2.7	51
75	Tandutinib (MLN518), a Potent FLT3 Inhibitor, Synergizes with Cytarabine and/or Daunorubicin in a Sequence-Independent Manner.. *Blood*, **2006**, 108, 1374-1374	2.2	2
74	A Novel, High-Throughput Assay for Detection of ABL T315I Mutations.. *Blood*, **2006**, 108, 2334-2334	2.2	
73	The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. *Blood*, **2005**, 106, 3377-9	2.2	319
72	Epidemiology of GIST. *American Journal of Gastroenterology*, **2005**, 100, 2366	0.7	21
71	Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. *Annals of Oncology*, **2005** , 16, 566-78	10.3	518
70	Gastrointestinal stromal tumors: insights from a new familial GIST kindred with unusual genetic and pathologic features. *American Journal of Surgical Pathology*, **2005**, 29, 1680-3	6.7	68
69	RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. *Blood*, **2005**, 105, 2952-4	2.2	36
68	In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. *Blood*, **2005**, 106, 227-34	2.2	52
67	Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. *Blood*, **2005**, 106, 2865-70	2.2	211
66	In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. *Blood*, **2005**, 106, 3532-7	2.2	28
65	In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. *Cancer Research*, **2005**, 65, 4500-5	10.1	904
64	Differences in the prevalence of PTPN11 mutations in FAB M5 paediatric acute myeloid leukaemia. *British Journal of Haematology*, **2005**, 130, 801-3	4.5	14
63	Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. *Leukemia*, **2005**, 19, 1536-42	10.7	199

62	A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib. *Leukemia*, **2005**, 19, 1859-62	10.7	17
61	Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy. *Journal of Surgical Oncology*, **2005**, 90, 195-207; discussion 207	2.8	94
60	The gene expression profile of extraskeletal myxoid chondrosarcoma. *Journal of Pathology*, **2005**, 206, 433-44	9.4	58
59	PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. *Journal of Clinical Oncology*, **2005**, 23, 5357-64	2.2	658
58	Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. *Journal of Clinical Oncology*, **2005**, 23, 866-73	2.2	374
57	Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. *Clinical Cancer Research*, **2005**, 11, 6987-93	12.9	88
56	Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. *Journal of Clinical Oncology*, **2005**, 23, 2735-43	2.2	129
55	In Chronic Myeloid Leukemia (CML) Patients with Complete Cytogenetic Response to Imatinib, BCR-ABL Kinase Domain Mutations Are Relatively Rare and Not Consistently Associated with Subsequent Relapse.. *Blood*, **2005**, 106, 434-434	2.2	1
54	A Gene Polymorphism within the Kinase Domain of BCR-ABL and Its Effects on Sensitivity to Tyrosine Kinase Inhibitors.. *Blood*, **2005**, 106, 1530-1530	2.2	
53	Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas. *Cancer Treatment and Research*, **2004**, 120, 129-50	3.5	4
52	Targeting FLT3 kinase in acute myelogenous leukemia: progress, perils, and prospects. *Mini-Reviews in Medicinal Chemistry*, **2004**, 4, 255-71	3.2	11
51	Biology of gastrointestinal stromal tumors: KIT mutations and beyond. *Cancer Investigation*, **2004**, 22, 106-16	2.1	63
50	Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). *Cancer Research*, **2004**, 64, 5127-31	10.1	101
49	High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. *The Hematology Journal*, **2004**, 5, 55-60		100
48	Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography. *Leukemia*, **2004**, 18, 864-71	10.7	55
47	Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. *Oncogene*, **2004**, 23, 7780-90	9.2	121
46	Pure red cell aplasia associated with parvovirus B19 infection occurring late after allogeneic bone marrow transplantation. *American Journal of Hematology*, **2004**, 75, 142-5	7.1	24
45	Biology of gastrointestinal stromal tumors. *Journal of Clinical Oncology*, **2004**, 22, 3813-25	2.2	907

44	KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors. *Journal of Molecular Diagnostics*, **2004**, 6, 366-70	5.1	44
43	KIT mutations are common in testicular seminomas. *American Journal of Pathology*, **2004**, 164, 305-13	5.8	258
42	The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. *American Journal of Pathology*, **2004**, 165, 107-13	5.8	505
41	KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. *American Journal of Surgical Pathology*, **2004**, 28, 889-94	6.7	393
40	Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. *Blood*, **2004**, 104, 4202-9	2.2	108
39	Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. *Blood*, **2004**, 104, 2912-8	2.2	43
38	Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. *Blood*, **2004**, 103, 2929-35	2.2	49
37	Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. *Blood*, **2004**, 104, 3754-7	2.2	68
36	Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. *Journal of Clinical Investigation*, **2004**, 114, 379-88	15.9	218
35	Phase II Evaluation of the Tyrosine Kinase Inhibitor MLN518 in Patients with Acute Myeloid Leukemia (AML) Bearing a FLT3 Internal Tandem Duplication (ITD) Mutation.. *Blood*, **2004**, 104, 1792-1792	2.2	23
34	Various Mechanisms Underlie Cytogenetic Refractoriness to Imatinib.. *Blood*, **2004**, 104, 2091-2091	2.2	1
33	Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. *Journal of Clinical Oncology*, **2003**, 21, 4342-9	2.2	1885
32	Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. *Annals of Oncology*, **2003**, 14, 873-80	10.3	48
31	Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. *Cancer Chemotherapy and Pharmacology*, **2003**, 51, 261-5	3.5	63
30	Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 2007-18	3.4	52
29	SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. *Blood*, **2003**, 101, 3597-605	2.2	731
28	PDGFRA activating mutations in gastrointestinal stromal tumors. *Science*, **2003**, 299, 708-10	33.3	1863
27	Absence of BRAF and NRAS mutations in uveal melanoma. *Cancer Research*, **2003**, 63, 5761-6	10.1	145

26	An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. *Clinical Cancer Research*, **2003**, 9, 5465-76	12.9	221
25	Is KIT an important therapeutic target in small cell lung cancer?. *Clinical Cancer Research*, **2003**, 9, 5825-8	12.9	12
24	STI571: a paradigm of new agents for cancer therapeutics. *Journal of Clinical Oncology*, **2002**, 20, 325-34	2.2	159
23	Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. *Journal of Clinical Oncology*, **2002**, 20, 1692-703	2.2	497
22	A functional genomics approach to Kaposi© sarcoma. *Annals of the New York Academy of Sciences*, **2002**, 975, 180-91	6.5	22
21	The effects of the Fanconi anemia zinc finger (FAZF) on cell cycle, apoptosis, and proliferation are differentiation stage-specific. *Journal of Biological Chemistry*, **2002**, 277, 26327-34	5.4	28
20	SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. *Blood*, **2002**, 100, 2941-9	2.2	162
19	KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. *American Journal of Pathology*, **2002**, 160, 1567-72	5.8	366
18	Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *New England Journal of Medicine*, **2002**, 347, 472-80	59.2	3474
17	Clinical management of gastrointestinal stromal tumors: before and after STI-571. *Human Pathology*, **2002**, 33, 466-77	3.7	482
16	Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. *Human Pathology*, **2002**, 33, 484-95	3.7	365
15	Kaposi© sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. *Journal of Virology*, **2002**, 76, 8383-99	6.6	115
14	Gastrointestinal stromal tumors. *Current Treatment Options in Oncology*, **2001**, 2, 485-91	5.4	59
13	Fine-needle aspiration biopsy diagnosis of gastrointestinal stromal tumors using morphology, immunocytochemistry, and mutational analysis of c-kit. *Cancer*, **2001**, 93, 269-75	6.4	94
12	Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. *Blood*, **2000**, 96, 925-932	2.2	878
11	A human gene coding for a membrane-associated nucleic acid-binding protein. *Journal of Biological Chemistry*, **2000**, 275, 33655-62	5.4	41
10	Co-transduction of cDNAs for c-kit and steel factor into single CD34+ cord blood cells further enhances the growth of erythroid and multipotential progenitors. *Journal of Hematotherapy and Stem Cell Research*, **2000**, 9, 813-25		6
9	Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. *Blood*, **2000**, 96, 925-932	2.2	39

8	Posttranscriptional cell cycle-dependent regulation of human FANCC expression. *Blood*, **2000**, 95, 3970-7	2.2	7
7	Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. *Blood*, **2000**, 96, 925-32	2.2	256
6	Retroviral-Mediated Gene Transduction of c-kit Into Single Hematopoietic Progenitor Cells From Cord Blood Enhances Erythroid Colony Formation and Decreases Sensitivity to Inhibition by Tumor Necrosis Factor-? and Transforming Growth Factor-1. *Blood*, **1999**, 94, 2319-2332	2.2	25
5	DNA Cross-Linker Induced G2/M Arrest in Group C Fanconi Anemia Lymphoblasts Reflects Normal Checkpoint Function. *Blood*, **1998**, 91, 275-287	2.2	59
4	The Fanconi Anemia Group C Gene Product Is Located in Both the Nucleus and Cytoplasm of Human Cells. *Blood*, **1998**, 91, 1418-1425	2.2	71
3	Basic fibroblast growth factor and epidermal growth factor downmodulate the growth of hematopoietic cells in long-term stromal cultures. *Journal of Cellular Physiology*, **1995**, 165, 386-97	7	16
2	Metastatic intravagal paraganglioma. Case report and review of the literature. *American Journal of Medicine*, **1985**, 78, 1017-24	2.4	32
1	Gastrointestinal stromal tumours: origin and molecular oncology		1